Contrast agent

RSNA: Photon-Counting CT Enables Lower Contrast Media for Aortic Imaging

Retrieved on: 
Thursday, January 26, 2023
Photon, Linda, Radiological Society of North America, University, Risk, Kidney, Abdomen, Diagnosis, Education, Kidney disease, Environment, Agent handling, CTA, Health, DRS, Aorta, University Hospital of Zürich, Radiation, University of Texas Southwestern Medical Center, OAK, Aneurysm, Patient, Facial muscles, Interventional radiology, Teaching hospital, Contrast agent, RSNA, Society, Iodine, Research, Medical imaging, Radiology

OAK BROOK, Ill., Jan. 26, 2023 /PRNewswire-PRWeb/ -- Photon-counting detector CT reduces the amount of contrast needed for CT angiography (CTA) while maintaining image quality, according to a new study published today, January 26, in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • In addition, the supply of contrast media has suffered from shortages due to COVID-19-related disruptions in the pharmaceutical supply chain.
  • Photon-counting detector CT is a new technology that can acquire high-quality images at lower contrast media volume than conventional CT scanners that rely on energy-integrating detectors.
  • Photon-counting CT had a higher contrast-to-noise ratio, a key measure of image quality, which translates to a low-volume contrast media protocol.
  • "CT Angiography of the Aorta Using Photon-counting Detector CT with Reduced Contrast Media Volume."

Global Contrast Media Injectors Market (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, July 18, 2022
Medical Devices, Health, Lung, 3D ultrasound, Patient, Colon, Rectum, Data collection, Radiology, MRI, MI, Contrast agent, Magnetic resonance imaging, Industry, COVID-19, PACS, Growth, Prevalence, Cancer, Prostate cancer, Pain, PET, Breast, Patient safety, Tissue, CT, CM, EMR, Pharmaceutical industry, Medical imaging, Video game console, Potash

CM injectors find extensive applications in radiology, interventional cardiology, ambulatory surgical centers (ASCs), and diagnostic imaging centers across the globe.

Key Points: 
  • CM injectors find extensive applications in radiology, interventional cardiology, ambulatory surgical centers (ASCs), and diagnostic imaging centers across the globe.
  • Key Questions Answered in This Report:
    How has the global contrast media injectors market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global contrast media injectors market?
  • What is the structure of the global contrast media injectors market and who are the key players?

Global Contrast Media/Contrast Agent Market Forecast to 2026 - Asia is Expected to Offer Strong Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021
Medical devices, Health, Materials, Physical sciences, Chemistry, Contrast agent, Iodinated contrast, Gadolinium, Market

The global contrast media/contrast agents market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.

Key Points: 
  • The global contrast media/contrast agents market is projected to reach USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.
  • Emerging markets in Asian countries are expected to offer strong growth opportunities for players in the market.
  • The contrast media/contrast agents market is segmented based on type, modality, route of administration, indication, application, end user, and region.
  • Based on type, the contrast media/contrast agents market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barum-based contrast media.

Global Contrast Media Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021
Medical Supplies, Health, Medical physics, Radiology, Medicine, Radiation, Medical imaging, Applied sciences, Medical tests, CT scan, Multidimensional signal processing, Magnetic resonance imaging, X-ray, Contrast agent

The "Contrast Media Market Share, Size, Trends, Industry Analysis Report, By Application; By Product; By Modality; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contrast Media Market Share, Size, Trends, Industry Analysis Report, By Application; By Product; By Modality; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global contrast media market size is expected to reach USD 5.33 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • Contrast media are used to improve internal images produced by MRI, CT scans, X-rays and allows radiologists to the difference between normal and diseased tissues.

Global Contrast Agents/Media Market to 2027 - Increasing Demand for Diagnostic and Interventional Radiology Procedures Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021
Radiology, Health, Medical physics, Physical sciences, Medical imaging, Materials, Medicine, Cryogenics, Magnetic resonance imaging, Radiology, Contrast agent, Gadolinium, Interventional radiology, CT scan

The "Contrast Agents/Media Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contrast Agents/Media Global Market - Forecast To 2027" report has been added to ResearchAndMarkets.com's offering.
  • According to this report the contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence & prevalence of chronic diseases and demand for diagnostic & interventional radiology procedures, increase in aging population, Expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement.
  • Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or interventional imaging investigation are known as contrast agents.
  • X-ray and computed tomography (CT) imaging exams make use of iodinated and barium-based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging).

RSNA: Cardiac MRI Contrast Agents Carry Low Risk of Adverse Events

Retrieved on: 
Thursday, October 29, 2020
Physical sciences, Magnetic resonance imaging, Chemistry, Materials, Cryogenics, Cardiac magnetic resonance imaging, Contrast agent, Gadolinium, Gado, Myocarditis, Radiology, MRI contrast agent

OAK BROOK, Ill., Oct. 29, 2020 /PRNewswire-PRWeb/ -- Contrast agents used to improve views of the heart on MRI carry a very low risk of allergic reactions, vomiting and other acute adverse events, according to a large study from Europe published in Radiology: Cardiothoracic Imaging .

Key Points: 
  • OAK BROOK, Ill., Oct. 29, 2020 /PRNewswire-PRWeb/ -- Contrast agents used to improve views of the heart on MRI carry a very low risk of allergic reactions, vomiting and other acute adverse events, according to a large study from Europe published in Radiology: Cardiothoracic Imaging .
  • The majority of cardiac MRI exams use intravenous gadolinium-based contrast agents (GBCAs) to improve visualization of the heart muscle and blood flow.
  • Contrast-enhanced cardiac MRI is also frequently used to evaluate diseases like cardiomyopathy and myocarditis.
  • "Gadolinium-based Contrast Agents for Cardiac MRI: Use of Linear and Macrocyclic Agents with Associated Safety Profile from 154,779 European Patients."

HKBU invents novel MRI contrast agent for Alzheimer's disease diagnosis

Retrieved on: 
Thursday, October 29, 2020
Physical sciences, Chemistry, Materials, Medical physics, Cryogenics, Magnetic resonance imaging, MRI contrast agent, Medical imaging, Gadolinium(III) oxide, Contrast agent, Gadolinium, Alzheimer's disease

Real-time visualisation of A contents in the brain is crucial for the diagnosis of AD and the monitoring of the disease's progression.

Key Points: 
  • Real-time visualisation of A contents in the brain is crucial for the diagnosis of AD and the monitoring of the disease's progression.
  • MRI is a more widely used clinical imaging tool, which requires a contrast agent to enhance the visibility of targeted objects in a specific location.
  • However, at present there is no clinically approved MRI contrast agent available for the real-time imaging of A in human brains.
  • "By modifying the surface functionalized layer of the gadolinium-based nanoparticles, we have developed a versatile and sensitive MRI contrast agent for the diagnosis of Alzheimer's disease which was proved effective in the mouse model," said Professor Wong.

HKBU invents novel MRI contrast agent for Alzheimer's disease diagnosis

Retrieved on: 
Thursday, October 29, 2020
Physical sciences, Chemistry, Materials, Medical physics, Cryogenics, Magnetic resonance imaging, MRI contrast agent, Medical imaging, Gadolinium(III) oxide, Contrast agent, Gadolinium, Alzheimer's disease

Real-time visualisation of A contents in the brain is crucial for the diagnosis of AD and the monitoring of the disease's progression.

Key Points: 
  • Real-time visualisation of A contents in the brain is crucial for the diagnosis of AD and the monitoring of the disease's progression.
  • MRI is a more widely used clinical imaging tool, which requires a contrast agent to enhance the visibility of targeted objects in a specific location.
  • However, at present there is no clinically approved MRI contrast agent available for the real-time imaging of A in human brains.
  • "By modifying the surface functionalized layer of the gadolinium-based nanoparticles, we have developed a versatile and sensitive MRI contrast agent for the diagnosis of Alzheimer's disease which was proved effective in the mouse model," said Professor Wong.

GE Healthcare’s Clariscan™ (gadoterate meglumine) Becomes Only FDA-Approved MRI Contrast Agent Available in Polymer Bottle

Retrieved on: 
Tuesday, September 15, 2020
Biotechnology, FDA, Medical devices, Health, Pharmaceutical, Physical sciences, Chemistry, Materials, MRI contrast agent, Gadoteric acid, Gadolinium, Contrast agent, Magnetic resonance imaging, GE Healthcare, General Electric, Gado, Biotechnology, FDA, Medical devices, Health, Pharmaceutical, Physical sciences, Chemistry, Materials, MRI contrast agent, Gadoteric acid, Gadolinium, Contrast agent, Magnetic resonance imaging, GE Healthcare, General Electric, Gado

GE Healthcares innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine).

Key Points: 
  • GE Healthcares innovative shatterproof polymer +PLUSPAK Pharmacy Bulk Package has been approved by the US FDA for use with its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine).
  • As the only FDA approved MRI contrast agent in a polymer bottle, Clariscan in +PLUSPAK will offer MRI departments a variety of ways in which they can improve safety and workflow efficiency.
  • Many radiology departments have already experienced the benefits of +PLUSPAK with other GE Healthcare contrast media products, said Dr Mark Hibberd, Chief Medical Officer for GE Healthcares Pharmaceutical Diagnostics unit.
  • Clariscan is available in single dose vials of 10, 15 and 20 mL and now 100 mL Pharmacy Bulk Package in an innovative +PLUSPAK polymer bottle.

FDA Urged to Remove Boxed Warnings on Ultrasound Contrast Agents

Retrieved on: 
Monday, August 31, 2020
Medical devices, FDA, Health, Other Health, Radiology, Cardiology, Medical ultrasonography, Medical equipment, Acoustics, Medicine, Biological engineering, Cardiology, Contrast-enhanced ultrasound, Applied sciences, Contrast agent, Imaging agent, Microbubble, Ultrasound

A grassroots medical society today urged the FDA to remove boxed warnings from ultrasound contrast agents (UCAs), citing compelling scientific data demonstrating their safety and life-saving potential.

Key Points: 
  • A grassroots medical society today urged the FDA to remove boxed warnings from ultrasound contrast agents (UCAs), citing compelling scientific data demonstrating their safety and life-saving potential.
  • The FDA will remove a black box when clinical evidence demonstrates that risks are less severe than previously thought, the ICUS Petition states.
  • UCAs (sometimes also known as ultrasound enhancing agents) are radiation-free imaging agents comprised of biocompatible suspensions of tiny gas-filled microbubbles that are injected intravenously during an ultrasound exam.
  • The International Contrast Ultrasound Society (ICUS) is a grassroots, non-profit medical society dedicated to advancing the safe and appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care.